Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis

{"BACKGROUND:":[0],"In":[1],"patients":[2,64,84,179,245,253,278,286,296],"with":[3,182,208,219,247,255,280,288,297,332,339],"infective":[4,118,166,298,348],"endocarditis":[5,119,167,299],"on":[6,27,300],"the":[7,11,13,63,68,86,94,301,305,307,328],"left":[8,302],"side":[9,303],"of":[10,16,21,74,138,163,177,304,309,343,345],"heart,":[12,306],"current":[14],"recommendation":[15],"up":[17],"to":[18,52,71,103,185,190,206,217,232,267,334],"6":[19,104,123,151],"weeks":[20,73],"antibiotic":[22,35,58,115,198,312,321],"therapy":[23,75,187,210,221,249,257,282,290,322,325],"is":[24,45],"based":[25],"largely":[26],"expert":[28],"consensus":[29],"opinion.":[30],"Whether":[31],"a":[32,136,169,310,316,340],"clinical":[33,80],"response-tailored":[34,55,186,311],"management":[36],"strategy":[37,313],"can":[38],"shorten":[39],"treatment":[40,99,116,199],"duration":[41],"without":[42,114,197,320],"compromising":[43],"safety":[44,132,239,335],"unclear.":[46],"METHODS:":[47],",":[48],"or":[49,56,120,146,165,347],"streptococcus":[50],"species":[51],"receive":[53],"either":[54],"standard-duration":[57,191,324],"therapy.":[59,192],"Before":[60],"randomization,":[61,83,181],"all":[62],"received":[65],"at":[66],"least":[67],"prespecified":[69],"2":[70],"4":[72,102,285],"and":[76,91,188,211,250,283,326,354],"met":[77,327],"criteria":[78],"for":[79,117,128,156,235,270,330],"stabilization.":[81],"After":[82],"in":[85,93,243,251,276,284,315],"tailored-therapy":[87],"group":[88,96],"discontinued":[89],"antibiotics":[90],"those":[92],"standard-therapy":[95],"continued":[97],"standard":[98,220,256,289],"(total":[100],"duration,":[101],"weeks).":[105],"The":[106,130,193],"primary":[107,131,238],"efficacy":[108],"end":[109,133,172],"point":[110,134],"was":[111,135,168,200,337],"days":[112,202,213],"alive":[113,196,319],"bacteremia":[121,164,346],"within":[122,150],"months":[124,152],"after":[125,153],"randomization":[126,154],"(tested":[127,155],"superiority).":[129,236],"composite":[137],"death":[139],"from":[140],"any":[141],"cause,":[142],"unplanned":[143],"cardiac":[144],"surgery,":[145],"symptomatic":[147],"embolic":[148],"events":[149],"noninferiority;":[157],"margin,":[158],"7.5":[159],"percentage":[160,262],"points).":[161],"Relapse":[162,274],"key":[170],"secondary":[171],"point.":[173],"RESULTS:":[174],"A":[175,237],"total":[176],"508":[178],"underwent":[180],"255":[183],"assigned":[184],"253":[189],"median":[194],"time":[195,318],"183":[201],"(interquartile":[203,214],"range,":[204,215],"181":[205],"183)":[207],"tailored":[209,248,281],"169":[212],"166":[216],"171)":[218],"(Hodges-Lehmann":[222],"estimated":[223],"difference,":[224,260],"13":[225,277],"days;":[226],"95%":[227,264],"confidence":[228],"interval":[229],"[CI],":[230],"12":[231],"13;":[233],"P<0.001":[234,269],"end-point":[240],"event":[241],"occurred":[242,275],"21":[244],"(8.2%)":[246],"27":[252],"(10.7%)":[254],"(absolute":[258],"between-group":[259],"-2.4":[261],"points;":[263],"CI,":[265],"-7.7":[266],"2.7;":[268],"noninferiority),":[271],"indicating":[272],"noninferiority.":[273],"(5.1%)":[279],"(1.6%)":[287],"(P":[291],"=":[292],"0.04).":[293],"CONCLUSIONS:":[294],"Among":[295],"use":[308],"resulted":[314],"longer":[317],"than":[323],"criterion":[329],"noninferiority":[331],"respect":[333],"but":[336],"associated":[338],"higher":[341],"incidence":[342],"relapse":[344],"endocarditis.":[349],"(Funded":[350],"by":[351],"Sygeforsikringen":[352],"\\"danmark\\"":[353],"others;":[355],"POET":[356],"II":[357],"ClinicalTrials.gov":[358],"number,":[359],"NCT03851575.).":[360]}

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2026-08-28
DOI
https://doi.org/10.1056/nejmoa2607887
Primary Topic
Infective Endocarditis Diagnosis and Management
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis

Jonas Agerlund Povlsen, Magnus Rasmussen, Lars Ege Rasmussen, Malene Wienberg et al.
New England Journal of Medicine
Infective Endocarditis Diagnosis and Management
article

Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis

Jonas Agerlund Povlsen, Magnus Rasmussen, Lars Ege Rasmussen, Malene Wienberg, Theis Lange, Ann E. Woolley, Ekim Seven, Søren Fanø, Mia Pries- Heje, Marlene Tofterup, Rasmus Hasselbalch, Christian Tuxen, Nareen Kader, Nana Køber, Lindsey R. Baden, Niels Eske Bruun, Julie Hjulmand, Jannik Helweg-Larsen, Henning Bundgaard, Peter Godsk Jørgensen, Claus Moser, Kasper Iversen, Emil Fosbøl
article en

Abstract

BACKGROUND: In patients with infective endocarditis on the left side of the heart, the current recommendation of up to 6 weeks of antibiotic therapy is based largely on expert consensus opinion. Whether a clinical response-tailored antibiotic management strategy can shorten treatment duration without compromising safety is unclear. METHODS: , or streptococcus species to receive either response-tailored or standard-duration antibiotic therapy. Before randomization, all the patients received at least the prespecified 2 to 4 weeks of therapy and met criteria for clinical stabilization. After randomization, patients in the tailored-therapy group discontinued antibiotics and those in the standard-therapy group continued standard treatment (total duration, 4 to 6 weeks). The primary efficacy end point was days alive without antibiotic treatment for infective endocarditis or bacteremia within 6 months after randomization (tested for superiority). The primary safety end point was a composite of death from any cause, unplanned cardiac surgery, or symptomatic embolic events within 6 months after randomization (tested for noninferiority; margin, 7.5 percentage points). Relapse of bacteremia or infective endocarditis was a key secondary end point. RESULTS: A total of 508 patients underwent randomization, with 255 assigned to response-tailored therapy and 253 to standard-duration therapy. The median time alive without antibiotic treatment was 183 days (interquartile range, 181 to 183) with tailored therapy and 169 days (interquartile range, 166 to 171) with standard therapy (Hodges-Lehmann estimated difference, 13 days; 95% confidence interval [CI], 12 to 13; P<0.001 for superiority). A primary safety end-point event occurred in 21 patients (8.2%) with tailored therapy and in 27 patients (10.7%) with standard therapy (absolute between-group difference, -2.4 percentage points; 95% CI, -7.7 to 2.7; P<0.001 for noninferiority), indicating noninferiority. Relapse occurred in 13 patients (5.1%) with tailored therapy and in 4 patients (1.6%) with standard therapy (P = 0.04). CONCLUSIONS: Among patients with infective endocarditis on the left side of the heart, the use of a response-tailored antibiotic strategy resulted in a longer time alive without antibiotic therapy than standard-duration therapy and met the criterion for noninferiority with respect to safety but was associated with a higher incidence of relapse of bacteremia or infective endocarditis. (Funded by Sygeforsikringen "danmark" and others; POET II ClinicalTrials.gov number, NCT03851575.).

New England Journal of Medicine
University of Copenhagen (DK), Brigham and Women's Hospital (US), Harvard University (US), Lund University (SE), Aalborg University Hospital (DK), Amager Hospital (DK), Novo Nordisk Foundation (DK), Frederiksberg Hospital (DK), Odense University Hospital (DK), Herlev Hospital (DK), Aarhus University Hospital (DK), Copenhagen University Hospital (DK), Gentofte Hospital (DK), Rigshospitalet (DK), North Denmark Region (DK), Zealand University Hospital (DK), Dana-Farber Cancer Institute (US), Skåne University Hospital (SE)
Arvid Nilssons Fond, Augustinus Fonden, Rigshospitalet, Thora og Viggo Groves Mindelegat, Danmarks Frie Forskningsfond, William Demant Fonden
Good health and well-being
Openalex Percentile: Top 10%
Infective Endocarditis Diagnosis and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.